Last updated 2026-06-18
- Acquired by NLS Pharmaceutics, Oct 2025
- Went public
- Raised $5M funding round led by Clover Wolf Capital, Oct 2021
Total raised
$45.4M
Last: Grant 2025-07
Stage
Mature
Founded
2008
Headcount
29
HQ
Ness Ziona, Israel
Sector
Health Tech & Life Sciences
About
NewCelX is a biotechnology company developing transformative cell-based and small-molecule therapies for neurodegenerative and metabolic diseases. The company’s integrated platform combines advanced stem-cell technologies and neuroscience expertise to deliver scalable, regenerative treatments targeting conditions such as Amyotrophic Lateral Sclerosis (ALS) and Type 1 Diabetes.
Funding history · 7 rounds · $45.4M total
2025-07
Grant
$882K
2022-12
Grant
$1.0M
2021-11
$3.2M
2021-10
2021-04
2018-11
Grant
$750K
Q&A
- What is NewCelX's primary focus?
- NewCelX is a biotechnology company dedicated to developing cell-based and small-molecule therapies for neurodegenerative and metabolic diseases, including Amyotrophic Lateral Sclerosis (ALS) and Type 1 Diabetes.
- When was NewCelX acquired and by whom?
- NewCelX was acquired by NLS Pharmaceutics in October 2025.
- Has NewCelX received any recent grants?
- Yes, in July 2025, NewCelX received an $882,000 grant from the BIRD Foundation.
- What was a significant funding event for NewCelX in 2021?
- In April 2021, NewCelX raised $6.8 million in a funding round led by Alpha Capital. Later, in October 2021, they raised another $5 million with Clover Wolf Capital as a lead investor.
- What is the employee count for NewCelX?
- NewCelX has an employee count in the 11-50 range.
- What was NewCelX's most recent public offering?
- NewCelX had a public offering in October 2025 on NASDAQ under the stock symbol NCEL.
- What was a key strategic collaboration announced by NewCelX in October 2025?
- In October 2025, NewCelX announced a strategic collaboration with TargetGene to advance next-generation gene-edited cell therapies.
- What recent development has NewCelX made regarding its Type 1 Diabetes treatment?
- In May 2026, NewCelX Ltd. submitted a Pre-IND Package to the FDA for NCEL-101 for the treatment of Type 1 Diabetes.
- What is the status of NewCelX's intellectual property regarding its diabetes treatment?
- In February 2024, NewCelX (formerly Kadimastem) received a patent for its cell selection and enrichment technology used to develop its IsletRx treatment for diabetes in India.
Team · 1
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
BiologicalsCells
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business model
B2B
Highlights
1 Patents
Tags
pharma-companiesstem-cellsdiabetesdegenerative-diseasesbioprocessneurologycell-therapyregenerative-medicinebiological-therapyamyotrophic-lateral-sclerosis-als
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | newcelx.com/ |
|---|---|
| linkedin.com/company/1515403 | |
| facebook.com/pg/Kadimastem | |
| YouTube | youtube.com/channel/UCou93PD-i8aPBZCXZiQ4G7Q |
Identifiers & details
| Legal name | NewCelX Ltd. |
|---|---|
| Former names | Kadimastem |
| Founded | 2008-10 |
| Employees (exact) | 29 |
| Offices | Kloten |
| Market cap | $8.7M |
| Status reason | Public on NASDAQ on Oct, 2025; |
Acquisitions & public offerings
Acquired by NLS Pharmaceutics 2025-10
| Type | Date | Exchange | Ticker | Amount |
|---|---|---|---|---|
| Jun 2013 | $20.4M | |||
| Jan 2023 | $2.2M | |||
| Oct 2025 |
Radar intelligence
Web history (Wayback)
| Domain | newcelx.com |
|---|
Certificate / subdomain footprint
| Subdomains | 3 |
|---|